Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 3/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495448 | 0.89 | RHOA (0.53) | CTSCCHEK2SYKCTSLAURKA | |
| SCHEMBL5513122 | 0.85 | CTSC (0.52) | CTSCCHEK2CHEK1CTSL | |
| SCHEMBL5523916 | 0.85 | KCNK3 (0.52) | CTSCSYKCTSLAURKA | |
| SCHEMBL5508263 | 0.85 | CHEK2 (0.56) | CTSCCHEK2CHEK1SYKCTSL | |
| SCHEMBL5500805 | 0.84 | RHOA (0.48) | CTSCCHEK2SYKCTSLAURKA | |
| SCHEMBL29818028 | 0.83 | HDAC1 (0.60) | CHEK2CHEK1SYKROCK1CDK19 | |
| SCHEMBL5509168 | 0.82 | AURKA (0.46) | CTSCCHEK2CHEK1SYKCTSL | |
| SCHEMBL5499607 | 0.81 | CTSC (0.62) | CTSCSYKCTSL | |
| SCHEMBL5494755 | 0.81 | CTSC (0.64) | CTSCSYKCTSLAURKA | |
| SCHEMBL5499937 | 0.80 | ROCK1 (0.48) | CTSCCHEK2CHEK1ROCK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293484-A1 | Thiophene Heteroaryl Amines | SUGEN, INC. | 2007-12-20 | — | — | US | claimed |
| EP-1753750-A1 | THIOPHENE HETEROARYL AMINES | Sugen, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| WO-2005113548-A1 | THIOPHENE HETEROARYL AMINES | SUGEN, INC. (US) | 2005-12-01 | — | — | WO | claimed |
| US-20070293484-A1 | Thiophene Heteroaryl Amines | SUGEN, INC. | 2007-12-20 | — | — | US | disclosed |
| EP-1753750-A1 | THIOPHENE HETEROARYL AMINES | Sugen, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005113548-A1 | THIOPHENE HETEROARYL AMINES | SUGEN, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293484-A1 | Thiophene Heteroaryl Amines | TTK, CHEK2, ABL1 | CTSC 2987/4885CHEK2 2/4885CHEK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.